Research at Oslo University Hospital

 

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

 

Latest news

Jan Terje Andersen receives a grant of 8.5 million NOK from NANO2021

 
Jan Terje Andersen
Jan Terje Andersen

The Laboratory of Adaptive Immunity and Homeostasis, headed by Jan Terje Andersen, is studying the cellular processes and molecular interplay underlying the functions of the two most abundant proteins in blood, albumin and IgG. By combining structural and biophysical approaches with cellular and in vivo studies, they use the insights to design novel albumin and antibody molecules with improved functions. The research group has now received a grant of 8.5 million NOK from The research Council of Norway (NANO2021 program) to expand their work on how such engineered ligands can be explored in combination with nanoparticles for tailored mucosal delivery. The project is entitled “A novel nanoparticle-based approach for mucosal delivery of therapeutics".
There were 61 applicants, of which two (including this application) obtained the highest possible rate. 

 
 

Professor Kjetil Taskén is presented as new director of the Department of Cancer Research at the Cancer Clinic, Oslo University Hospital

 
Kjetil Taskén
Kjetil Taskén

Taskén`s current position is Director of the Center for Molecular Medicine Norway – NCMM (merged with the Biotechnology center in 2017). He will begin in his position as Head of Department in January 2018.

Kjetil Taskén is 51 years old (born December 19, 1965), and he is a highly qualified and experienced research leader with very relevant background as head of a large unit for biomedical research (120-180 employees at NCMM).

Taskén is an active researcher who can be credited for a total of 269 publications, and well over 12,000 citations. He also holds an h-index of 59 within both basic research and translational research. In 2016, he was awarded the prestigious King Olavs Vs Cancer Research Prize for his work on immunotherapy, a field of expertise that Taskén has been involved in ever since he started his research in 1994. Furthermore, he also leads one of six research groups in the KG Jebsen Center for cancer Immunotherapy (led by Johanna Olweus).

 
 

Nature Communications publication:

Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors

 
From left: Jiqui Cheng, Hege Russnes, Ole Chr. Lingjærde and Peter Van Loo
From left: Jiqui Cheng, Hege Russnes, Ole Chr. Lingjærde and Peter Van Loo

The authors demonstrate the power of meta-analysis to identify rare somatic variants in cancer, and they identify several copy number alterations of potential importance for tumor development in those affected. The paper contributes to the understanding of the diversity of evolutionary processes in cancer.
The study, published online in Nature Communications on 31 October, is collaboration between OUS, UiO and several international partners. First author Jiqiu Cheng from the Hege Russnes group at the Department of Cancer Genetics at the Institute for Cancer Research. The senior author of the paper is Peter Van Loo at the Francis Crick Institute in UK.

 
 

Scandic Holmenkollen Park, December 4-6, 2017:

The Norwegian Cancer symposium 2017 on Precision Medicine

 

We would like to extend an invitation to The Norwegian Cancer symposium 2017 on Precision Medicine
It will take place at Scandic Holmenkollen Park, December 4-6, 2017 in Oslo, Norway.

The meeting gathers leading national and international speakers in the field of precision medicine, and topics include the following:

  • Computational Cancer Genomics
  • Tumor Immunology and the microenvironment
  • Single cell analysis for disease trajectories and Liquid Biopsies
  • Monitoring cancer genetics in body fluids
  • Translational and clinical genomics

There are still some few seats available.
Registration will close at Sunday November 19.

 
 

Nature Communications publication:

A study of the epigenetics of breast cancer provides clues to mechanisms behind subtypes of the disease

 
Photo: Daniel Nebdal.<br>
(image capiton under
Photo: Daniel Nebdal.
(image capiton under "More")

Thomas Fleischer and Xavier Tekpli from the Cancer Genome Variation group,  lead by Vessela Kristensen at the Department of Cancer Genetics, IKF, together with their collaborators from the NCMM, Toni Hurtado and Anthony Mathelier, and Professor Arnoldo Frigessi from UiO identified methylated regions (CpGs) that show remarkably and reproducibly conserved patterns of association to gene expression in the DNA from breast tumors in three independent breast cancer cohorts. These patterns result in two main signatures (clusters), one reflecting infiltrating immune cell signatures and another related to estrogen receptor signalling. These results indicate that, in at least some forms of cancer, aberrant DNA methylation occurs not as chaotic stochastic process but is precisely regulated. 
The results were published online in Nature Communications November 9th .

 
 

Ceremony Friday November 10th

Ragnar Mørk legacy prize 2017 to June Myklebust

 
June H. Myklebust
June H. Myklebust

The 2017 "Dr. Ragnar Mørk's legacy prize" went to June Helen Myklebust from Erlend B. Smeland's Lymphomas & Lymphocyte Biology Group at the Department of Cancer Immunology. This award of NOK 200.000 is annually given to scientists affiliated to the Norwegian Radium Hospital who have obtained important results within the field of cancer research.
The ceremony took place on Friday November 10th in the Research Building at Montebello.
June Helen Myklebust gave a lecture about the research activities that has earned her the award.
The article is updated with photos from the ceremony.

 
 

Maria Torgersen receives a grant of 8.5 million NOK from NANO2021

 
Maria Torgersen
Maria Torgersen

Maria Torgersen, researcher in the group of Kirsten Sandvig in Department of Molecular Cell Biology, is presently working in NANOCAN, the national competence building project of nanomedicine including 10 research groups in Norway. Maria has now received a grant of 8.5 million NOK from The research Council of Norway (NANO2021 program) to continue her work with studies of the importance of autophagy in cellular responses to uptake of nanoparticles. The project is entitled “nanoAUTOPHAGY – health implications of nanoparticle-induced changes in autophagy”. The grant includes salary for 4 years for Maria and 3 years for a PhD student. There were 61 applicants, of which two (including Maria) obtained the highest possible rate.

 
 

Nature Communications article from OCBE:

Inequality in genetic cancer risk: Bad genes or bad luck?

 
Mats J. Stensrud (left) and Morten Valberg
Mats J. Stensrud (left) and Morten Valberg

Which factors increase the risk of cancer? What is the relative importance of heritable factors, the environment and randomness? Such questions often lead to discussions and speculations, which unfortunately tend to be imprecise. In a recent publication in Nature Communications, researchers Mats J. Stensrud and Morten Valberg from Oslo Centre for Biostatistics and Epidemiology (OCBE) use statistical methods to quantify the distribution of genetic cancer risk in a population. Their results show that genes have a major influence on the risk of cancer. For 15 common cancers, the inequality in genetic cancer risk is larger than the inequality in income in the USA.

 
 

Rusten group uncovers new regulatory mechanism of the Peutz-Jeghers cancer syndrome kinase, LKB1

 
Team at Centre for Cancer Biomedicine behind the study
Team at Centre for Cancer Biomedicine behind the study

Structural breakdown of epithelial architecture is a cardinal hallmark of carcinomas - the most common forms of cancer.
Our cells contain tumor suppressor genes that act as gate-keepers to prevent tumor growth. One such classical tumor suppressor, Liver Kinase B1 (LKB1), was identified as being responsible for the hereditary cancer predisposition syndrome, Peutz-Jeghers syndrome. It has later been shown to be mutated in other cancer types, such as lung cancer.
Reporting this week in the prestigeous journal Nature Cell Biology (IF 20,6), O´Farrell and colleagues now reports that intracellular endocytic trafficking of LKB1 is essential to curtail Lkb1 activity from going rogue. In a surprising twist, they show that LKB1 can act to promote carcinogenesis, a role normally possessed by oncogenes.

 
 

New collaboration between the Olweus research group and Kite Pharma

 
Johanna Olweus
Johanna Olweus

The research group of Johanna Olweus at the Department of Immunology at the Institute for Cancer Research is entering into a collaboration with Kite Pharma in order to develop breakthrough technology on immunotherapy against cancer.
As one of the three major companies in the world leading the development of immunotherapy, Kite Pharma has the resources and expertise to carry out major clinical studies.
"The starting point for the collaboration is that we have developed the technology they are interested in. In the last five years we have been looking for new immunogens encoding T cell receptors, for use in cancer treatment," says Olweus.